Ponatinib for CML that didn’t respond to prior pills
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies ponatinib as a second treatment for chronic myeloid leukemia (CML) when it didn’t fully respond or couldn’t be tolerated with at least one prior CML pill. It aims to see whether ponatinib can better control leukemia levels after earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CML in the chronic phase, with a specific leukemia marker (Ph-positive or BCR-ABL-positive).
- Your prior CML pills (imatinib, dasatinib, nilotinib, or bosutinib) didn’t work well enough or caused side effects, based on standard blood and chromosome response rules.
- Your leukemia testing shows ongoing disease changes, such as loss of a good response (like CCyR) or new mutations/chromosome changes during treatment.
- You’re over 18, and your overall functioning is fairly good (ECOG 0–2).
- Your heart condition and major organs (liver, kidneys) are healthy enough for treatment based on lab checks.
- You must not be pregnant or breastfeeding, and you (or a partner if you can get pregnant) must use effective birth control during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This study looks at how the drug ponatinib works in people with chronic phase CML. It aims to understand how the body handles the drug and if it helps control the leukemia.
This trial tests a targeted therapy called ponatinib in children whose leukemia, lymphoma, or solid tumor has come back or hasn't improved with standard treatments. The drug works by blocking signals that help cancer cells grow, and the study looks at how safe and effective it is for different cancer types.
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
Hear when a new Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.